Plenary Paper

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua D. Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Danielle L. Chappell, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, and John C. Byrd

[1]  K. Lam,et al.  Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs , 2012, Molecular Pharmacology.

[2]  J. Byrd,et al.  The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.

[3]  Jeffrey A Jones,et al.  A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. , 2012 .

[4]  Defeng Wu,et al.  Role of Itk signalling in the interaction between influenza A virus and T-cells. , 2012, The Journal of general virology.

[5]  R. Baiocchi,et al.  Novel targeted therapies for mantle cell lymphoma , 2012, Oncotarget.

[6]  C. Harrison.  Trial watch: BTK inhibitor shows positive results in B cell malignancies , 2012, Nature Reviews Drug Discovery.

[7]  S. Im,et al.  Enhanced Chromatin Accessibility and Recruitment of JUNB Mediate the Sustained IL-4 Expression in NFAT1 Deficient T Helper 2 Cells , 2011, PloS one.

[8]  W. Robinson,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells , 2011, Arthritis research & therapy.

[9]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[10]  P. Schwartzberg,et al.  Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross‐regulation of cytokine production and T‐cell fates , 2011, The FEBS journal.

[11]  C. I. Smith,et al.  TEC family kinases in health and disease – loss‐of‐function of BTK and ITK and the gain‐of‐function fusions ITK–SYK and BTK–SYK , 2011, The FEBS journal.

[12]  R. Advani,et al.  The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study , 2010 .

[13]  Douglas H. Thamm,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.

[14]  E. Forbes,et al.  Differential requirements for IL‐4/STAT6 signalling in CD4 T‐cell fate determination and Th2‐immune effector responses , 2010, Immunology and cell biology.

[15]  L. Silvian,et al.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases , 2010, Protein science : a publication of the Protein Society.

[16]  V. Morrison.  Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. , 2010, Best practice & research. Clinical haematology.

[17]  R. Advani,et al.  A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. , 2009 .

[18]  A. Sher,et al.  Selective Expression Rather than Specific Function of Txk and Itk Regulate Th1 and Th2 Responses1 , 2008, The Journal of Immunology.

[19]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[20]  P. Schwartzberg,et al.  Selective targeting of ITK blocks multiple steps of HIV replication , 2008, Proceedings of the National Academy of Sciences.

[21]  E. Sotomayor,et al.  Cellular and molecular mechanisms of tumor-induced T-cell tolerance. , 2007, Current cancer drug targets.

[22]  P. Schwartzberg,et al.  Altered development of CD8+ T cell lineages in mice deficient for the Tec kinases Itk and Rlk. , 2006, Immunity.

[23]  D. Fowell,et al.  Cutting Edge: Itk-Dependent Signals Required for CD4+ T Cells to Exert, but Not Gain, Th2 Effector Function1 , 2006, The Journal of Immunology.

[24]  L. Atherly,et al.  Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help. , 2006, The Journal of Immunology.

[25]  H. Mellstedt,et al.  T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil , 2006, Cancer Immunology, Immunotherapy.

[26]  M. Croft,et al.  Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Gribben,et al.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.

[28]  Heather M. Wilcox,et al.  Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. , 2004, Immunity.

[29]  C. Cancrini,et al.  Bruton's tyrosine kinase defect in dendritic cells from X‐linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen‐presenting cell function , 2003, Clinical and experimental immunology.

[30]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[31]  A. Prentice,et al.  Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia , 2003, Leukemia & lymphoma.

[32]  P. Lydyard,et al.  Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B‐chronic lymphocytic leukaemia (B‐CLL) , 2001, Clinical and experimental immunology.

[33]  H. Nagafuchi,et al.  Txk, a Nonreceptor Tyrosine Kinase of the Tec Family, Is Expressed in T Helper Type 1 Cells and Regulates Interferon γ Production in Human T Lymphocytes , 1999, The Journal of experimental medicine.

[34]  R. Coffman,et al.  Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. , 1999, Immunity.

[35]  H. Varmus,et al.  Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. , 1999, Science.

[36]  S. Bunnell,et al.  T Cell Receptor–initiated Calcium Release Is Uncoupled from Capacitative Calcium Entry in Itk-deficient T Cells , 1998, The Journal of experimental medicine.

[37]  A. Hoerauf,et al.  The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. , 1994, International immunology.

[38]  J. Ceuppens,et al.  Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism. , 1993, Immunology.

[39]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  H. Lo.  Itk inhibitors : a patent review , 2010 .

[41]  J. Pinilla-Ibarz,et al.  Circumventing immune tolerance through epigenetic modification. , 2010, Current pharmaceutical design.

[42]  K. Rai,et al.  Chronic lymphocytic leukemia: current and emerging treatment approaches. , 2006, Clinical advances in hematology & oncology : H&O.

[43]  P. Schwartzberg,et al.  Tec family kinases in T lymphocyte development and function. , 2005, Annual review of immunology.

[44]  S. Chiplunkar.  Immune system and cancer. , 1988, Princess Takamatsu symposia.